Chips · Stock report · Murata Manufacturing (TSE: 6981.T)
Murata — back above its 200-day line at 0.17%, yet ranked 70 of 86 chip stocks over a month
The Closelooknet read
Murata Manufacturing (TSE: 6981.T) crossed back above the average close of the last 200 sessions on Tuesday, but only just: it closed at ¥6,367 against ¥6,356.07, which is 0.17% above the line. Over one month it is down 20.6%, which ranks 70th of the 86 stocks in our chip section. Our money-flow reading (a gauge of net buying pressure) is 118.3, still positive but slowing, with a fall of 28.4 points over 21 sessions. What we watch: whether it closes above ¥6,356.07 in the coming sessions, or slips back under it.
Our momentum score is 36.
Where Murata stands among our chip stocks
Murata's one-month fall of 20.6% puts it in the lower part of our section, at 70 of 86. Its peers across venues are also lower over the month, though by different amounts. Sumco (TSE: 3436.T) is down 23.3%, GlobalWafers (6488.TW) 16.2%, Siltronic (WAF.DE) 16.6%, Soitec (SOI.PA) 14.5% and Resonac (TSE: 4004.T) 13.7%. Shin-Etsu Chemical (4063.T) is down 0.7% and Entegris (ENTG) 0.4%.
Murata sits 48.0% below its 52-week closing high of ¥12,250 from 22 June. Sumco is 55.0% below its July high; Entegris is 18.4% below its June high.
Our money-flow reading
Our money-flow reading for Murata is 118.3, labelled warm in our scheme. It is still positive but slowing: it is down 10.6 points over five sessions and 28.4 over 21 sessions. Our momentum score is 36. Only one of our scoring modules has data for Murata, so no composite score or financial-health check is shown.
Price trend
Murata rose 2.7% on Tuesday and opened with a 4.2% gap up. It is up 96.2% this year and 124.0% over one year, but down 4.2% over five sessions, 20.6% over a month and 25.4% over three months. It trades 14.7% below its 50-day average of ¥7,460.96. Its typical daily swing is about 4.8%. A stochastic momentum signal turned up from oversold three sessions ago, with %K at 13.1 over %D at 10.1.
Closelooknet is a research diary. Nothing here is investment advice or a recommendation to buy or sell.